Dianthus Therapeutics, Inc. - Common Stock (DNTH)

Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of its late-stage trial.

The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years of dominance by a handful of "Magnificent 7" companies, the tide has turned toward the "median stock,

This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC disclosure.

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.

The company is working on a treatment for an autoimmune disease that affects the muscles.

Dianthus's claseprubart showed rapid, meaningful improvements in gMG symptoms with a favorable safety profile in Phase 2 MaGic trial results.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026.

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.